ID   TRY1_HUMAN              Reviewed;         247 AA.
AC   P07477; A1A509; A6NJ71; B2R5I5; Q5NV57; Q7M4N3; Q7M4N4; Q92955; Q9HAN4;
AC   Q9HAN5; Q9HAN6; Q9HAN7;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   22-FEB-2023, entry version 226.
DE   RecName: Full=Serine protease 1 {ECO:0000312|HGNC:HGNC:9475};
DE            EC=3.4.21.4;
DE   AltName: Full=Anionic trypsin I {ECO:0000250|UniProtKB:P00762};
DE   AltName: Full=Anionic trypsin-I {ECO:0000250|UniProtKB:P00762};
DE   AltName: Full=Beta-trypsin;
DE   AltName: Full=Cationic trypsinogen;
DE   AltName: Full=Pretrypsinogen I {ECO:0000250|UniProtKB:P00762};
DE   AltName: Full=Trypsin I {ECO:0000312|HGNC:HGNC:9475};
DE   AltName: Full=Trypsin-1;
DE   Contains:F
DE     RecName: Full=Alpha-trypsin chain 1;
DE   Contains:
DE     RecName: Full=Alpha-trypsin chain 2;
DE   Flags: Precursor;
GN   Name=PRSS1 {ECO:0000312|HGNC:HGNC:9475};
GN   Synonyms=TRP1, TRY1 {ECO:0000312|HGNC:HGNC:9475}, TRYP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3011602; DOI=10.1016/0378-1119(86)90111-3;
RA   Emi M., Nakamura Y., Ogawa M., Yamamoto T., Nishide T., Mori T.,
RA   Matsubara K.;
RT   "Cloning, characterization and nucleotide sequences of two cDNAs encoding
RT   human pancreatic trypsinogens.";
RL   Gene 41:305-310(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8650574; DOI=10.1126/science.272.5269.1755;
RA   Rowen L., Koop B.F., Hood L.;
RT   "The complete 685-kilobase DNA sequence of the human beta T cell receptor
RT   locus.";
RL   Science 272:1755-1762(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 15-67, AND VARIANT PCTT GLY-22.
RX   PubMed=10930381; DOI=10.1053/gast.2000.9312;
RA   Teich N., Ockenga J., Hoffmeister A., Manns M., Mossner J., Keim V.;
RT   "Chronic pancreatitis associated with an activation peptide mutation that
RT   facilitates trypsin activation.";
RL   Gastroenterology 119:461-465(2000).
RN   [9]
RP   PROTEIN SEQUENCE OF 16-43 AND 123-142, FUNCTION, AND POST-TRANSLATIONAL
RP   PROCESSING.
RC   TISSUE=Gastric adenocarcinoma;
RX   PubMed=7945238; DOI=10.1042/bj3030187;
RA   Koshikawa N., Yasumitsu H., Nagashima Y., Umeda M., Miyazaki K.;
RT   "Identification of one- and two-chain forms of trypsinogen 1 produced by a
RT   human gastric adenocarcinoma cell line.";
RL   Biochem. J. 303:187-190(1994).
RN   [10]
RP   PROTEIN SEQUENCE OF 16-43.
RX   PubMed=2598466; DOI=10.1016/0009-8981(89)90254-4;
RA   Kimland M., Russick C., Marks W.H., Borgstroem A.;
RT   "Immunoreactive anionic and cationic trypsin in human serum.";
RL   Clin. Chim. Acta 184:31-46(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 68-151, AND VARIANT PCTT HIS-122.
RX   PubMed=8841182; DOI=10.1038/ng1096-141;
RA   Whitcomb D.C., Gorry M.C., Preston R.A., Furey W., Sossenheimer M.J.,
RA   Ulrich C.D., Martin S.P., Gates L.K. Jr., Amann S.T., Toskes P.P.,
RA   Liddle R., McGrath K., Uomo G., Post J.C., Ehrlich G.D.;
RT   "Hereditary pancreatitis is caused by a mutation in the cationic
RT   trypsinogen gene.";
RL   Nat. Genet. 14:141-145(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 68-151, AND VARIANTS PCTT ILE-29;
RP   PRO-104; CYS-116; HIS-122 AND PHE-139.
RX   PubMed=11866271; DOI=10.1111/j.1572-0241.2002.05467.x;
RA   Teich N., Bauer N., Mossner J., Keim V.;
RT   "Mutational screening of patients with nonalcoholic chronic pancreatitis:
RT   identification of further trypsinogen variants.";
RL   Am. J. Gastroenterol. 97:341-346(2002).
RN   [13]
RP   PROTEIN SEQUENCE OF 73-92, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Afjehi-Sadat L.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [14]
RP   SULFATION AT TYR-154, AND MUTAGENESIS OF TYR-154.
RX   PubMed=17087724; DOI=10.1111/j.1742-4658.2006.05501.x;
RA   Sahin-Toth M., Kukor Z., Nemoda Z.;
RT   "Human cationic trypsinogen is sulfated on Tyr154.";
RL   FEBS J. 273:5044-5050(2006).
RN   [15]
RP   SULFATION AT TYR-154.
RX   PubMed=25010489; DOI=10.1371/journal.pone.0102063;
RA   Szabo A., Salameh M.A., Ludwig M., Radisky E.S., Sahin-Toth M.;
RT   "Tyrosine sulfation of human trypsin steers S2' subsite selectivity towards
RT   basic amino acids.";
RL   PLoS ONE 9:E102063-E102063(2014).
RN   [16]
RP   INTERACTION WITH SERPINA1.
RX   PubMed=11057674; DOI=10.1038/35038119;
RA   Huntington J.A., Read R.J., Carrell R.W.;
RT   "Structure of a serpin-protease complex shows inhibition by deformation.";
RL   Nature 407:923-926(2000).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), AND MASS SPECTROMETRY.
RX   PubMed=8683601; DOI=10.1006/jmbi.1996.0376;
RA   Gaboriaud C., Serre L., Guy-Crotte O., Forest E., Fontecilla-Camps J.-C.;
RT   "Crystal structure of human trypsin 1: unexpected phosphorylation of
RT   Tyr151.";
RL   J. Mol. Biol. 259:995-1010(1996).
RN   [18]
RP   VARIANTS PCTT ILE-29 AND HIS-122.
RX   PubMed=9322498; DOI=10.1053/gast.1997.v113.pm9322498;
RA   Gorry M.C., Gabbaizedeh D., Furey W., Gates L.K. Jr., Preston R.A.,
RA   Aston C.E., Zhang Y., Ulrich C., Ehrlich G.D., Whitcomb D.C.;
RT   "Mutations in the cationic trypsinogen gene are associated with recurrent
RT   acute and chronic pancreatitis.";
RL   Gastroenterology 113:1063-1068(1997).
RN   [19]
RP   VARIANT PCTT ILE-29.
RX   PubMed=9633818;
RX   DOI=10.1002/(sici)1098-1004(1998)12:1<39::aid-humu6>3.0.co;2-p;
RA   Teich N., Mossner J., Keim V.;
RT   "Mutations of the cationic trypsinogen in hereditary pancreatitis.";
RL   Hum. Mutat. 12:39-43(1998).
RN   [20]
RP   VARIANTS PCTT VAL-16 AND HIS-122.
RX   PubMed=10381903; DOI=10.1016/s0016-5085(99)70543-3;
RA   Witt H., Luck W., Becker M.;
RT   "A signal peptide cleavage site mutation in the cationic trypsinogen gene
RT   is strongly associated with chronic pancreatitis.";
RL   Gastroenterology 117:7-10(1999).
RN   [21]
RP   VARIANT PCTT ARG-23.
RX   PubMed=10204851;
RA   Ferec C., Raguenes O., Salomon R., Roche C., Bernard J.P., Guillot M.,
RA   Quere I., Faure C., Mercier B., Audrezet M.-P., Guillausseau P.J.,
RA   Dupont C., Munnich A., Bignon J.D., Le Bodic L.;
RT   "Mutations in the cationic trypsinogen gene and evidence for genetic
RT   heterogeneity in hereditary pancreatitis.";
RL   J. Med. Genet. 36:228-232(1999).
RN   [22]
RP   VARIANT PCTT HIS-122.
RX   PubMed=11073545; DOI=10.1136/jmg.37.11.e36;
RA   Chen J.-M., Raguenes O., Ferec C., Deprez P.H., Verellen-Dumoulin C.;
RT   "A CGC>CAT gene conversion-like event resulting in the R122H mutation in
RT   the cationic trypsinogen gene and its implication in the genotyping of
RT   pancreatitis.";
RL   J. Med. Genet. 37:E36-E36(2000).
RN   [23]
RP   VARIANTS PCTT THR-29 AND CYS-122.
RX   PubMed=11788572; DOI=10.1136/gut.50.2.271;
RA   Pfutzer R., Myers E., Applebaum-Shapiro S., Finch R., Ellis I.,
RA   Neoptolemos J., Kant J.A., Whitcomb D.C.;
RT   "Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause
RT   autosomal dominant hereditary pancreatitis.";
RL   Gut 50:271-272(2002).
RN   [24]
RP   VARIANT PCTT LYS-79, AND CHARACTERIZATION OF VARIANT PCTT LYS-79.
RX   PubMed=14695529; DOI=10.1002/humu.10285;
RA   Teich N., Le Marechal C., Kukor Z., Caca K., Witzigmann H., Chen J.-M.,
RA   Toth M., Moessner J., Keim V., Ferec C., Sahin-Toth M.;
RT   "Interaction between trypsinogen isoforms in genetically determined
RT   pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased
RT   transactivation of anionic trypsinogen (PRSS2).";
RL   Hum. Mutat. 23:22-31(2004).
RN   [25]
RP   VARIANTS PCTT ILE-29 AND SER-54, AND CHARACTERIZATION OF VARIANTS PCTT
RP   ILE-29 AND SER-54.
RX   PubMed=15776435; DOI=10.1002/humu.20148;
RA   Teich N., Nemoda Z., Koehler H., Heinritz W., Moessner J., Keim V.,
RA   Sahin-Toth M.;
RT   "Gene conversion between functional trypsinogen genes PRSS1 and PRSS2
RT   associated with chronic pancreatitis in a six-year-old girl.";
RL   Hum. Mutat. 25:343-347(2005).
RN   [26]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-137.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Has activity against the synthetic substrates Boc-Phe-Ser-
CC       Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-
CC       Mec. The single-chain form is more active than the two-chain form
CC       against all of these substrates. {ECO:0000269|PubMed:7945238}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa.; EC=3.4.21.4;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- SUBUNIT: Interacts with SERPINA1. {ECO:0000269|PubMed:11057674}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- PTM: Occurs in a single-chain form and a two-chain form, produced by
CC       proteolytic cleavage after Arg-122.
CC   -!- PTM: Sulfation at Tyr-154 increases selectivity towards basic versus
CC       apolar residues at the P2' position of inhibitors that bind in a
CC       substrate-like fashion. Although the increase in selectivity is
CC       relatively small, it may facilitate digestion of a broader range of
CC       dietary proteins. {ECO:0000269|PubMed:25010489}.
CC   -!- MASS SPECTROMETRY: [Serine protease 1]: Mass=24348; Mass_error=2;
CC       Method=Electrospray; Evidence={ECO:0000269|PubMed:8683601};
CC   -!- DISEASE: Pancreatitis, hereditary (PCTT) [MIM:167800]: A disease
CC       characterized by pancreas inflammation, permanent destruction of the
CC       pancreatic parenchyma, maldigestion, and severe abdominal pain attacks.
CC       {ECO:0000269|PubMed:10204851, ECO:0000269|PubMed:10381903,
CC       ECO:0000269|PubMed:10930381, ECO:0000269|PubMed:11073545,
CC       ECO:0000269|PubMed:11788572, ECO:0000269|PubMed:11866271,
CC       ECO:0000269|PubMed:14695529, ECO:0000269|PubMed:15776435,
CC       ECO:0000269|PubMed:8841182, ECO:0000269|PubMed:9322498,
CC       ECO:0000269|PubMed:9633818}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- CAUTION: Tyr-154 was proposed to be phosphorylated (PubMed:8683601) but
CC       it has been shown (PubMed:17087724) to be sulfated instead. Phosphate
CC       and sulfate groups are similar in mass and size, and this can lead to
CC       erroneous interpretation of the results. {ECO:0000305|PubMed:17087724,
CC       ECO:0000305|PubMed:8683601}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M22612; AAA61231.1; -; mRNA.
DR   EMBL; L36092; AAC80207.1; -; Genomic_DNA.
DR   EMBL; AK312199; BAG35132.1; -; mRNA.
DR   EMBL; AC231380; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236959; EAL23773.1; -; Genomic_DNA.
DR   EMBL; CH471198; EAW51925.1; -; Genomic_DNA.
DR   EMBL; BC128226; AAI28227.1; -; mRNA.
DR   EMBL; AF314534; AAG30943.1; -; Genomic_DNA.
DR   EMBL; U70137; AAC50728.1; -; Genomic_DNA.
DR   EMBL; AF315309; AAG30947.1; -; Genomic_DNA.
DR   EMBL; AF315310; AAG30948.1; -; Genomic_DNA.
DR   EMBL; AF315311; AAG30949.1; -; Genomic_DNA.
DR   CCDS; CCDS5872.1; -.
DR   PIR; A25852; A25852.
DR   PIR; S50020; S50020.
DR   PIR; S50021; S50021.
DR   RefSeq; NP_002760.1; NM_002769.4.
DR   PDB; 1FXY; X-ray; 2.15 A; A=127-247.
DR   PDB; 1TRN; X-ray; 2.20 A; A/B=24-247.
DR   PDB; 2RA3; X-ray; 1.46 A; A/B=24-247.
DR   PDB; 4WWY; X-ray; 1.70 A; A/B=24-247.
DR   PDB; 4WXV; X-ray; 2.10 A; A/B=24-247.
DR   PDB; 7QE8; X-ray; 2.90 A; A/B=24-247.
DR   PDB; 7QE9; X-ray; 2.10 A; A/B=24-247.
DR   PDBsum; 1FXY; -.
DR   PDBsum; 1TRN; -.
DR   PDBsum; 2RA3; -.
DR   PDBsum; 4WWY; -.
DR   PDBsum; 4WXV; -.
DR   PDBsum; 7QE8; -.
DR   PDBsum; 7QE9; -.
DR   AlphaFoldDB; P07477; -.
DR   SMR; P07477; -.
DR   BioGRID; 111626; 67.
DR   IntAct; P07477; 19.
DR   MINT; P07477; -.
DR   STRING; 9606.ENSP00000308720; -.
DR   BindingDB; P07477; -.
DR   ChEMBL; CHEMBL209; -.
DR   DrugBank; DB02665; (1R,2S)-2-Phenylcyclopropanaminium.
DR   DrugBank; DB03417; (2S,3R)-2-[[4-(Tert-butylcarbamoyl)piperazine-1-carbonyl]amino]-6-(diaminomethylideneamino)-3-formylhexanoic acid.
DR   DrugBank; DB06850; (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB07091; (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB06845; (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB07088; (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB07131; (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB07095; (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide.
DR   DrugBank; DB04793; 1,4:3,6-Dianhydro-2-O-(3-carbamimidoylphenyl)-5-O-(4-carbamimidoylphenyl)-D-glucitol.
DR   DrugBank; DB03337; 1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea.
DR   DrugBank; DB04336; 1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea.
DR   DrugBank; DB08420; 1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID.
DR   DrugBank; DB04790; 2,5-bis-O-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-D-glucitol.
DR   DrugBank; DB04792; 2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL.
DR   DrugBank; DB01905; 2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine.
DR   DrugBank; DB02463; 2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine.
DR   DrugBank; DB02287; 2-(2-hydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine.
DR   DrugBank; DB08184; 2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE.
DR   DrugBank; DB06918; 2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE.
DR   DrugBank; DB06923; 2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE.
DR   DrugBank; DB08254; 2-Naphthalenesulfonic acid.
DR   DrugBank; DB04791; 2-O-(4'-AMIDINOPHENYL)-5-O-(3''-AMIDINOPHENYL)-1,4:3,6-DIANHYDRO-D-SORBITOL.
DR   DrugBank; DB01725; 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide.
DR   DrugBank; DB01665; 2H-Benzimidazol-2-amine.
DR   DrugBank; DB03374; 3,5-Diiodotyrosine.
DR   DrugBank; DB04410; 3-Phenylpropylamine.
DR   DrugBank; DB07229; 3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE.
DR   DrugBank; DB07368; 4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE.
DR   DrugBank; DB03243; 4-Fluorobenzylamine.
DR   DrugBank; DB03136; 4-Iodobenzo[B]Thiophene-2-Carboxamidine.
DR   DrugBank; DB04311; 4-Phenylbutylamine.
DR   DrugBank; DB04654; 4-PIPERIDIN-4-YLBUTANAL.
DR   DrugBank; DB02354; 4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine.
DR   DrugBank; DB01939; 5-Amidino-Benzimidazole.
DR   DrugBank; DB07491; 5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid.
DR   DrugBank; DB03865; 6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine.
DR   DrugBank; DB06855; 6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine.
DR   DrugBank; DB04107; [(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester.
DR   DrugBank; DB01836; [4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone.
DR   DrugBank; DB02269; [4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium.
DR   DrugBank; DB08763; [N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE.
DR   DrugBank; DB03081; [N-[N-(4-Methoxy-2,3,6-trimethylphenylsulfonyl)-L-aspartyl]-D-(4-amidino-phenylalanyl)]-piperidine.
DR   DrugBank; DB04391; Aeruginosin 98-B.
DR   DrugBank; DB02435; Aminomethylcyclohexane.
DR   DrugBank; DB02045; Amylamine.
DR   DrugBank; DB06692; Aprotinin.
DR   DrugBank; DB03127; Benzamidine.
DR   DrugBank; DB04446; Benzo[B]Thiophene-2-Carboxamidine.
DR   DrugBank; DB02464; Benzylamine.
DR   DrugBank; DB03213; Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone.
DR   DrugBank; DB04301; Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate.
DR   DrugBank; DB01876; Bis(5-Amidino-2-Benzimidazolyl)Methanone.
DR   DrugBank; DB01705; Bis(5-Amidino-Benzimidazolyl)Methane.
DR   DrugBank; DB03443; bis(5-amidino-benzimidazolyl)methanone zinc.
DR   DrugBank; DB02081; Bis-Benzamidine.
DR   DrugBank; DB13729; Camostat.
DR   DrugBank; DB02288; CRA-9334.
DR   DrugBank; DB03173; CRA_10433.
DR   DrugBank; DB02526; CRA_10655.
DR   DrugBank; DB04470; CRA_10656.
DR   DrugBank; DB02366; CRA_10762.
DR   DrugBank; DB02989; CRA_10972.
DR   DrugBank; DB01771; CRA_10991.
DR   DrugBank; DB03555; CRA_11092.
DR   DrugBank; DB03643; CRA_1144.
DR   DrugBank; DB02063; CRA_16847.
DR   DrugBank; DB02084; CRA_17312.
DR   DrugBank; DB01741; CRA_17693.
DR   DrugBank; DB03016; CRA_1801.
DR   DrugBank; DB02875; CRA_1802.
DR   DrugBank; DB04246; CRA_23653.
DR   DrugBank; DB03159; CRA_8696.
DR   DrugBank; DB04215; CRA_9076.
DR   DrugBank; DB04563; CRA_9678.
DR   DrugBank; DB03595; CRA_9785.
DR   DrugBank; DB04269; Cyclotheonamide A.
DR   DrugBank; DB06840; diethyl [(1R)-1,5-diaminopentyl]boronate.
DR   DrugBank; DB03608; Diminazene.
DR   DrugBank; DB12831; Gabexate.
DR   DrugBank; DB01767; Hemi-Babim.
DR   DrugBank; DB04442; Imino[2-(2-oxo-1,2-dihydro-3-pyridinyl)-1H-benzimidazol-5-yl]methanaminium.
DR   DrugBank; DB07985; METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE.
DR   DrugBank; DB01805; Monoisopropylphosphorylserine.
DR   DrugBank; DB04125; N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)-4-Acetyl-Piperazine.
DR   DrugBank; DB01745; N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester.
DR   DrugBank; DB04238; N-Alpha-(2-Naphthylsulfonyl)-N-(3-Amidino-L-Phenylalaninyl)-D-Pipecolinic Acid.
DR   DrugBank; DB06853; N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide.
DR   DrugBank; DB06858; N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide.
DR   DrugBank; DB12598; Nafamostat.
DR   DrugBank; DB01737; Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester.
DR   DrugBank; DB04325; Phenethylamine.
DR   DrugBank; DB03976; Phosphorylisopropane.
DR   DrugBank; DB04424; RPR128515.
DR   DrugBank; DB02744; RPR131247.
DR   DrugBank; DB03251; RWJ-51084.
DR   DrugBank; DB02812; RWJ-56423.
DR   DrugBank; DB03876; Thieno[2,3-B]Pyridine-2-Carboxamidine.
DR   DrugBank; DB04008; Zinc;[amino-[2-[[5-[amino(azaniumylidene)methyl]benzimidazol-1-id-2-yl]methyl]benzimidazol-1-id-5-yl]methylidene]azanium.
DR   DrugBank; DB04432; ZK-805623.
DR   DrugBank; DB02112; Zk-806450.
DR   DrugBank; DB03373; ZK-806711.
DR   DrugCentral; P07477; -.
DR   GuidetoPHARMACOLOGY; 2397; -.
DR   MEROPS; S01.127; -.
DR   iPTMnet; P07477; -.
DR   PhosphoSitePlus; P07477; -.
DR   BioMuta; PRSS1; -.
DR   DMDM; 136408; -.
DR   EPD; P07477; -.
DR   jPOST; P07477; -.
DR   MassIVE; P07477; -.
DR   PaxDb; P07477; -.
DR   PeptideAtlas; P07477; -.
DR   ProteomicsDB; 52006; -.
DR   Antibodypedia; 18375; 544 antibodies from 37 providers.
DR   DNASU; 5644; -.
DR   Ensembl; ENST00000311737.12; ENSP00000308720.7; ENSG00000204983.15.
DR   Ensembl; ENST00000616256.4; ENSP00000479217.1; ENSG00000274247.4.
DR   GeneID; 5644; -.
DR   KEGG; hsa:5644; -.
DR   MANE-Select; ENST00000311737.12; ENSP00000308720.7; NM_002769.5; NP_002760.1.
DR   UCSC; uc003wak.3; human.
DR   AGR; HGNC:9475; -.
DR   CTD; 5644; -.
DR   DisGeNET; 5644; -.
DR   GeneCards; PRSS1; -.
DR   GeneReviews; PRSS1; -.
DR   HGNC; HGNC:9475; PRSS1.
DR   HPA; ENSG00000204983; Tissue enriched (pancreas).
DR   MalaCards; PRSS1; -.
DR   MIM; 167800; phenotype.
DR   MIM; 276000; gene.
DR   neXtProt; NX_P07477; -.
DR   OpenTargets; ENSG00000204983; -.
DR   Orphanet; 676; Hereditary chronic pancreatitis.
DR   Orphanet; 64740; NON RARE IN EUROPE: Recurrent acute pancreatitis.
DR   PharmGKB; PA33828; -.
DR   VEuPathDB; HostDB:ENSG00000204983; -.
DR   eggNOG; KOG3627; Eukaryota.
DR   GeneTree; ENSGT01050000244883; -.
DR   InParanoid; P07477; -.
DR   OrthoDB; 4629979at2759; -.
DR   PhylomeDB; P07477; -.
DR   TreeFam; TF331065; -.
DR   PathwayCommons; P07477; -.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-9758881; Uptake of dietary cobalamins into enterocytes.
DR   SignaLink; P07477; -.
DR   SIGNOR; P07477; -.
DR   BioGRID-ORCS; 5644; 12 hits in 1126 CRISPR screens.
DR   ChiTaRS; PRSS1; human.
DR   EvolutionaryTrace; P07477; -.
DR   GeneWiki; Trypsin_1; -.
DR   GenomeRNAi; 5644; -.
DR   Pharos; P07477; Tclin.
DR   PRO; PR:P07477; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P07477; protein.
DR   Bgee; ENSG00000204983; Expressed in body of pancreas and 91 other tissues.
DR   ExpressionAtlas; P07477; baseline and differential.
DR   Genevisible; P07477; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0007586; P:digestion; IEA:UniProtKB-KW.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; IBA:GO_Central.
DR   CDD; cd00190; Tryp_SPc; 1.
DR   Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   InterPro; IPR018114; TRYPSIN_HIS.
DR   InterPro; IPR033116; TRYPSIN_SER.
DR   PANTHER; PTHR24264:SF57; TRYPSIN-1; 1.
DR   PANTHER; PTHR24264; TRYPSIN-RELATED; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Digestion; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Hydrolase; Metal-binding; Protease;
KW   Reference proteome; Secreted; Serine protease; Signal; Sulfation; Zymogen.
FT   SIGNAL          1..15
FT                   /evidence="ECO:0000269|PubMed:2598466,
FT                   ECO:0000269|PubMed:7945238"
FT   PROPEP          16..23
FT                   /note="Activation peptide"
FT                   /id="PRO_0000028197"
FT   CHAIN           24..247
FT                   /note="Serine protease 1"
FT                   /id="PRO_0000028198"
FT   CHAIN           24..122
FT                   /note="Alpha-trypsin chain 1"
FT                   /id="PRO_0000313570"
FT   CHAIN           123..247
FT                   /note="Alpha-trypsin chain 2"
FT                   /id="PRO_0000313571"
FT   DOMAIN          24..244
FT                   /note="Peptidase S1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00274"
FT   ACT_SITE        63
FT                   /note="Charge relay system"
FT   ACT_SITE        107
FT                   /note="Charge relay system"
FT   ACT_SITE        200
FT                   /note="Charge relay system"
FT   BINDING         75
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         77
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         80
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         85
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   SITE            194
FT                   /note="Required for specificity"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         154
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000305|PubMed:17087724,
FT                   ECO:0000305|PubMed:25010489"
FT   DISULFID        30..160
FT   DISULFID        48..64
FT   DISULFID        139..206
FT   DISULFID        171..185
FT   DISULFID        196..220
FT   VARIANT         16
FT                   /note="A -> V (in PCTT; disrupts signal sequence cleavage
FT                   site; dbSNP:rs202003805)"
FT                   /evidence="ECO:0000269|PubMed:10381903"
FT                   /id="VAR_011693"
FT   VARIANT         22
FT                   /note="D -> G (in PCTT; increased rate of activation;
FT                   dbSNP:rs397507442)"
FT                   /evidence="ECO:0000269|PubMed:10930381"
FT                   /id="VAR_011652"
FT   VARIANT         23
FT                   /note="K -> R (in PCTT; increased rate of activation;
FT                   dbSNP:rs111033567)"
FT                   /evidence="ECO:0000269|PubMed:10204851"
FT                   /id="VAR_011653"
FT   VARIANT         29
FT                   /note="N -> I (in PCTT; dbSNP:rs111033566)"
FT                   /evidence="ECO:0000269|PubMed:11866271,
FT                   ECO:0000269|PubMed:15776435, ECO:0000269|PubMed:9322498,
FT                   ECO:0000269|PubMed:9633818"
FT                   /id="VAR_006720"
FT   VARIANT         29
FT                   /note="N -> T (in PCTT; dbSNP:rs111033566)"
FT                   /evidence="ECO:0000269|PubMed:11788572"
FT                   /id="VAR_012712"
FT   VARIANT         54
FT                   /note="N -> S (in PCTT; associated with Ile-29; the double
FT                   mutant shows increased autocatalytic activation which is
FT                   solely due to the Ile-29 mutation; dbSNP:rs144422014)"
FT                   /evidence="ECO:0000269|PubMed:15776435"
FT                   /id="VAR_037908"
FT   VARIANT         79
FT                   /note="E -> K (in PCTT; Lys-79 trypsin activates anionic
FT                   trypsinogen PRSS2 2-fold while the common
FT                   pancreatitis-associated mutants His-122 or Ile-29 have no
FT                   such effect; dbSNP:rs111033564)"
FT                   /evidence="ECO:0000269|PubMed:14695529"
FT                   /id="VAR_037909"
FT   VARIANT         104
FT                   /note="L -> P (in PCTT; dbSNP:rs1554499091)"
FT                   /evidence="ECO:0000269|PubMed:11866271"
FT                   /id="VAR_011654"
FT   VARIANT         116
FT                   /note="R -> C (in PCTT; dbSNP:rs387906698)"
FT                   /evidence="ECO:0000269|PubMed:11866271"
FT                   /id="VAR_011655"
FT   VARIANT         122
FT                   /note="R -> C (in PCTT; suppresses an autocleavage site;
FT                   dbSNP:rs111033568)"
FT                   /evidence="ECO:0000269|PubMed:11788572"
FT                   /id="VAR_012713"
FT   VARIANT         122
FT                   /note="R -> H (in PCTT; suppresses an autocleavage site
FT                   which is probably part of a fail-safe mechanism by which
FT                   trypsin, which is activated within the pancreas, may be
FT                   inactivated; loss of this cleavage site would permit
FT                   autodigestion resulting in pancreatitis;
FT                   dbSNP:rs267606982)"
FT                   /evidence="ECO:0000269|PubMed:10381903,
FT                   ECO:0000269|PubMed:11073545, ECO:0000269|PubMed:11866271,
FT                   ECO:0000269|PubMed:8841182, ECO:0000269|PubMed:9322498"
FT                   /id="VAR_006721"
FT   VARIANT         137
FT                   /note="T -> M (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs117497341)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036299"
FT   VARIANT         139
FT                   /note="C -> F (in PCTT)"
FT                   /evidence="ECO:0000269|PubMed:11866271"
FT                   /id="VAR_011656"
FT   MUTAGEN         154
FT                   /note="Y->F: Lack of sulfation."
FT                   /evidence="ECO:0000269|PubMed:17087724"
FT   CONFLICT        4
FT                   /note="L -> F (in Ref. 7; AAI28227)"
FT                   /evidence="ECO:0000305"
FT   STRAND          38..54
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          57..60
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          70..74
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          76..80
FT                   /evidence="ECO:0007829|PDB:7QE9"
FT   STRAND          86..95
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   TURN            101..103
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          109..115
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          138..144
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          149..151
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          159..165
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   HELIX           168..174
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   TURN            176..178
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          183..187
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:1TRN"
FT   STRAND          203..206
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          209..216
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          218..222
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   STRAND          227..231
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   HELIX           232..235
FT                   /evidence="ECO:0007829|PDB:2RA3"
FT   HELIX           236..245
FT                   /evidence="ECO:0007829|PDB:2RA3"
SQ   SEQUENCE   247 AA;  26558 MW;  DD49A487B8062813 CRC64;
     MNPLLILTFV AAALAAPFDD DDKIVGGYNC EENSVPYQVS LNSGYHFCGG SLINEQWVVS
     AGHCYKSRIQ VRLGEHNIEV LEGNEQFINA AKIIRHPQYD RKTLNNDIML IKLSSRAVIN
     ARVSTISLPT APPATGTKCL ISGWGNTASS GADYPDELQC LDAPVLSQAK CEASYPGKIT
     SNMFCVGFLE GGKDSCQGDS GGPVVCNGQL QGVVSWGDGC AQKNKPGVYT KVYNYVKWIK
     NTIAANS
//
ID   LEP_MOUSE               Unreviewed;         167 AA.
AC   P41160;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DE   RecName: Full=Leptin;
DE   AltName: Full=Obesity factor;
DE   Flags: Precursor;
GN   Name=Lep; Synonyms=Ob;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7984236; DOI=10.1038/372425a0;
RA   Zhang Y., Proenca P., Maffei M., Barone M., Leopold L., Friedman J.M.;
RT   "Positional cloning of the mouse obese gene and its human homologue.";
RL   Nature 372:425-432(1994).
RN   [2]
RP   ERRATUM OF PUBMED:7984236.
RA   Zhang Y., Proenca P., Maffei M., Barone M., Leopold L., Friedman J.M.;
RL   Nature 374:479-479(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RA   Chehab F.F., Lim M.E.;
RL   Submitted (MAR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=8589726; DOI=10.1038/ng0396-318;
RA   Chehab F.F., Lim M.E., Lu R.;
RT   "Correction of the sterility defect in homozygous obese female mice by
RT   treatment with the human recombinant leptin.";
RL   Nat. Genet. 12:318-320(1996).
RN   [5]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=9732873; DOI=10.1038/29795;
RA   Lord G.M., Matarese G., Howard J.K., Baker R.J., Bloom S.R., Lechler R.I.;
RT   "Leptin modulates the T-cell immune response and reverses starvation-
RT   induced immunosuppression.";
RL   Nature 394:897-901(1998).
RN   [6]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=10660043; DOI=10.1016/s0092-8674(00)81558-5;
RA   Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T.,
RA   Shen J., Vinson C., Rueger J.M., Karsenty G.;
RT   "Leptin inhibits bone formation through a hypothalamic relay: a central
RT   control of bone mass.";
RL   Cell 100:197-207(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11373681; DOI=10.1038/35078085;
RA   Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S.,
RA   Horvath T.L., Cone R.D., Low M.J.;
RT   "Leptin activates anorexigenic POMC neurons through a neural network in the
RT   arcuate nucleus.";
RL   Nature 411:480-484(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=12594516; DOI=10.1038/nature01388;
RA   Bates S.H., Stearns W.H., Dundon T.A., Schubert M., Tso A.W., Wang Y.,
RA   Banks A.S., Lavery H.J., Haq A.K., Maratos-Flier E., Neel B.G.,
RA   Schwartz M.W., Myers M.G. Jr.;
RT   "STAT3 signalling is required for leptin regulation of energy balance but
RT   not reproduction.";
RL   Nature 421:856-859(2003).
RN   [9]
RP   REVIEW OF FUNCTION IN IMMUNITY.
RX   PubMed=15122202; DOI=10.1038/nri1350;
RA   La Cava A., Matarese G.;
RT   "The weight of leptin in immunity.";
RL   Nat. Rev. Immunol. 4:371-379(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15899045; DOI=10.1186/ar1708;
RA   Otero M., Lago R., Lago F., Reino J.J., Gualillo O.;
RT   "signaling pathway involved in nitric oxide synthase type II activation in
RT   chondrocytes: synergistic effect of leptin with interleukin-1.";
RL   Arthritis Res. Ther. 7:R581-R591(2005).
RN   [11]
RP   FUNCTION.
RX   PubMed=16825198; DOI=10.1074/jbc.m601991200;
RA   Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K.,
RA   Sullivan B.T., Sakamoto H., Olawaiye A., Serikawa T., Lynch M.P.,
RA   Rueda B.R.;
RT   "Leptin signaling promotes the growth of mammary tumors and increases the
RT   expression of vascular endothelial growth factor (VEGF) and its receptor
RT   type two (VEGF-R2).";
RL   J. Biol. Chem. 281:26320-26328(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=20620997; DOI=10.1016/j.cmet.2010.05.010;
RA   Ramadori G., Fujikawa T., Fukuda M., Anderson J., Morgan D.A.,
RA   Mostoslavsky R., Stuart R.C., Perello M., Vianna C.R., Nillni E.A.,
RA   Rahmouni K., Coppari R.;
RT   "SIRT1 deacetylase in POMC neurons is required for homeostatic defenses
RT   against diet-induced obesity.";
RL   Cell Metab. 12:78-87(2010).
RN   [13]
RP   REVIEW OF FUNCTION.
RX   PubMed=25232147; DOI=10.1530/joe-14-0404;
RA   Allison M.B., Myers M.G. Jr.;
RT   "20 years of leptin: connecting leptin signaling to biological function.";
RL   J. Endocrinol. 223:T25-T35(2014).
RN   [14]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=25060689; DOI=10.1016/j.metabol.2014.06.010;
RA   Cassano S., Pucino V., La Rocca C., Procaccini C., De Rosa V., Marone G.,
RA   Matarese G.;
RT   "Leptin modulates autophagy in human CD4+CD25- conventional T cells.";
RL   Metabolism 63:1272-1279(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=25383904; DOI=10.1038/nn.3861;
RA   Flak J.N., Patterson C.M., Garfield A.S., D'Agostino G., Goforth P.B.,
RA   Sutton A.K., Malec P.A., Wong J.M., Germani M., Jones J.C., Rajala M.,
RA   Satin L., Rhodes C.J., Olson D.P., Kennedy R.T., Heisler L.K.,
RA   Myers M.G. Jr.;
RT   "Leptin-inhibited PBN neurons enhance responses to hypoglycemia in negative
RT   energy balance.";
RL   Nat. Neurosci. 17:1744-1750(2014).
CC   -!- FUNCTION: Key player in the regulation of energy balance and body
CC       weight control. Once released into the circulation, has central and
CC       peripheral effects by binding LEPR, found in many tissues, which
CC       results in the activation of several major signaling pathways
CC       (PubMed:15899045, PubMed:16825198, PubMed:11373681, PubMed:12594516,
CC       PubMed:20620997). In the hypothalamus, acts as an appetite-regulating
CC       factor that induces a decrease in food intake and an increase in energy
CC       consumption by inducing anorexinogenic factors and suppressing
CC       orexigenic neuropeptides, also regulates bone mass and secretion of
CC       hypothalamo-pituitary-adrenal hormones. In the periphery, increases
CC       basal metabolism, influences reproductive function, regulates
CC       pancreatic beta-cell function and insulin secretion, is pro-angiogenic
CC       for endothelial cell and affects innate and adaptive immunity (By
CC       similarity) (PubMed:8589726, PubMed:10660043, PubMed:25383904,
CC       PubMed:25060689, PubMed:9732873, PubMed:12594516). In the arcuate
CC       nucleus of the hypothalamus, activates by depolarization POMC neurons
CC       inducing FOS and SOCS3 expression to release anorexigenic peptides and
CC       inhibits by hyperpolarization NPY neurons inducing SOCS3 with a
CC       consequent reduction on release of orexigenic peptides (By similarity)
CC       (PubMed:20620997, PubMed:11373681). In addition to its known satiety
CC       inducing effect, has a modulatory role in nutrient absorption. In the
CC       intestine, reduces glucose absorption by enterocytes by activating PKC
CC       and leading to a sequential activation of p38, PI3K and ERK signaling
CC       pathways which exerts an inhibitory effect on glucose absorption. Acts
CC       as a growth factor on certain tissues, through the activation of
CC       different signaling pathways increases expression of genes involved in
CC       cell cycle regulation such as CCND1, via JAK2-STAT3 pathway, or VEGFA,
CC       via MAPK1/3 and PI3K-AKT1 pathways (By similarity) (PubMed:16825198,
CC       PubMed:20620997). May also play an apoptotic role via JAK2-STAT3
CC       pathway and up-regulation of BIRC5 expression (By similarity). Pro-
CC       angiogenic, has mitogenic activity on vascular endothelial cells and
CC       plays a role in matrix remodeling by regulating the expression of
CC       matrix metalloproteinases (MMPs) and tissue inhibitors of
CC       metalloproteinases (TIMPs) (PubMed:16825198). In innate immunity,
CC       modulates the activity and function of neutrophils by increasing
CC       chemotaxis and the secretion of oxygen radicals. Increases phagocytosis
CC       by macrophages and enhances secretion of pro-inflammatory mediators.
CC       Increases cytotoxic ability of NK cells (Probable). Plays a pro-
CC       inflammatory role, in synergy with IL1B, by inducing NOS2 wich promotes
CC       the production of IL6, IL8 and Prostaglandin E2, through a signaling
CC       pathway that involves JAK2, PI3K, MAP2K1/MEK1 and MAPK14/p38
CC       (PubMed:15899045). In adaptive immunity, promotes the switch of memory
CC       T-cells towards T helper-1 cell immune responses (By similarity).
CC       Increases CD4(+)CD25(-) T cells proliferation and reduces autophagy
CC       during TCR (T cell receptor) stimulation, through MTOR signaling
CC       pathway activation and BCL2 up-regulation (PubMed:25060689).
CC       {ECO:0000250|UniProtKB:P41159, ECO:0000250|UniProtKB:P50596,
CC       ECO:0000269|PubMed:10660043, ECO:0000269|PubMed:11373681,
CC       ECO:0000269|PubMed:12594516, ECO:0000269|PubMed:15899045,
CC       ECO:0000269|PubMed:16825198, ECO:0000269|PubMed:20620997,
CC       ECO:0000269|PubMed:25060689, ECO:0000269|PubMed:25383904,
CC       ECO:0000269|PubMed:8589726, ECO:0000269|PubMed:9732873,
CC       ECO:0000305|PubMed:15122202, ECO:0000305|PubMed:25232147}.
CC   -!- INTERACTION:
CC       P41160; P48356: Lepr; NbExp=6; IntAct=EBI-16108810, EBI-2257257;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:25232147}.
CC   -!- DISEASE: Note=Defects in Lep are the cause of profound obesity and type
CC       II diabetes.
CC   -!- DISRUPTION PHENOTYPE: Mutants are severely obese and sterile
CC       (PubMed:8589726). Animals have an increased bone formation leading to
CC       high bone mass (PubMed:10660043). Have impaired T-cell immunity, Th2
CC       responses are favoured in mutants (PubMed:9732873). CD4(+)CD25(-) T-
CC       cells of mutant mice show high levels of autophagy (PubMed:25060689).
CC       {ECO:0000269|PubMed:10660043, ECO:0000269|PubMed:25060689,
CC       ECO:0000269|PubMed:8589726, ECO:0000269|PubMed:9732873}.
CC   -!- SIMILARITY: Belongs to the leptin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U18812; AAA64564.1; -; mRNA.
DR   EMBL; U22421; AAA64213.1; -; Genomic_DNA.
DR   CCDS; CCDS19955.1; -.
DR   PIR; S50863; LTMS.
DR   RefSeq; NP_032519.1; NM_008493.3.
DR   AlphaFoldDB; P41160; -.
DR   SMR; P41160; -.
DR   BioGRID; 201138; 4.
DR   CORUM; P41160; -.
DR   DIP; DIP-60999N; -.
DR   IntAct; P41160; 1.
DR   STRING; 10090.ENSMUSP00000067046; -.
DR   PhosphoSitePlus; P41160; -.
DR   CPTAC; CPTAC-1473; -.
DR   PaxDb; P41160; -.
DR   ProteomicsDB; 265060; -.
DR   Antibodypedia; 3389; 1467 antibodies from 43 providers.
DR   DNASU; 16846; -.
DR   Ensembl; ENSMUST00000069789.12; ENSMUSP00000067046.6; ENSMUSG00000059201.13.
DR   GeneID; 16846; -.
DR   KEGG; mmu:16846; -.
DR   UCSC; uc009bcv.1; mouse.
DR   AGR; MGI:104663; -.
DR   CTD; 3952; -.
DR   MGI; MGI:104663; Lep.
DR   VEuPathDB; HostDB:ENSMUSG00000059201; -.
DR   eggNOG; ENOG502S5K5; Eukaryota.
DR   GeneTree; ENSGT00390000011772; -.
DR   HOGENOM; CLU_132715_0_0_1; -.
DR   InParanoid; P41160; -.
DR   OMA; MRCGPLC; -.
DR   OrthoDB; 5346301at2759; -.
DR   PhylomeDB; P41160; -.
DR   TreeFam; TF105086; -.
DR   Reactome; R-MMU-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1).
DR   Reactome; R-MMU-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   BioGRID-ORCS; 16846; 0 hits in 79 CRISPR screens.
DR   ChiTaRS; H2-Ob; mouse.
DR   PRO; PR:P41160; -.
DR   Proteomes; UP000000589; Chromosome 6.
DR   RNAct; P41160; protein.
DR   Bgee; ENSMUSG00000059201; Expressed in thoracic mammary gland and 50 other tissues.
DR   ExpressionAtlas; P41160; baseline and differential.
DR   Genevisible; P41160; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0005179; F:hormone activity; ISO:MGI.
DR   GO; GO:1990460; F:leptin receptor binding; ISO:MGI.
DR   GO; GO:0051428; F:peptide hormone receptor binding; ISO:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:MGI.
DR   GO; GO:1990051; P:activation of protein kinase C activity; ISS:UniProtKB.
DR   GO; GO:0060612; P:adipose tissue development; IGI:MGI.
DR   GO; GO:0008343; P:adult feeding behavior; IDA:HGNC-UCL.
DR   GO; GO:0001525; P:angiogenesis; ISO:MGI.
DR   GO; GO:0035904; P:aorta development; IMP:MGI.
DR   GO; GO:0008206; P:bile acid metabolic process; IDA:MGI.
DR   GO; GO:0098868; P:bone growth; IMP:UniProtKB.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; ISO:MGI.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; ISO:MGI.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:MGI.
DR   GO; GO:0071298; P:cellular response to L-ascorbic acid; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0021954; P:central nervous system neuron development; IMP:MGI.
DR   GO; GO:0008203; P:cholesterol metabolic process; IGI:MGI.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0008340; P:determination of adult lifespan; IGI:MGI.
DR   GO; GO:0042755; P:eating behavior; IGI:MGI.
DR   GO; GO:0051541; P:elastin metabolic process; IMP:MGI.
DR   GO; GO:0006112; P:energy reserve metabolic process; ISO:MGI.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IGI:MGI.
DR   GO; GO:0009062; P:fatty acid catabolic process; ISO:MGI.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IGI:MGI.
DR   GO; GO:0006006; P:glucose metabolic process; IMP:MGI.
DR   GO; GO:0006114; P:glycerol biosynthetic process; ISO:MGI.
DR   GO; GO:0042445; P:hormone metabolic process; IMP:MGI.
DR   GO; GO:0030073; P:insulin secretion; IGI:MGI.
DR   GO; GO:0050892; P:intestinal absorption; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:MGI.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; ISO:MGI.
DR   GO; GO:0006629; P:lipid metabolic process; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0032099; P:negative regulation of appetite; IDA:HGNC-UCL.
DR   GO; GO:0038108; P:negative regulation of appetite by leptin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0061037; P:negative regulation of cartilage development; ISO:MGI.
DR   GO; GO:0070093; P:negative regulation of glucagon secretion; IDA:BHF-UCL.
DR   GO; GO:0046325; P:negative regulation of glucose import; ISS:UniProtKB.
DR   GO; GO:2000486; P:negative regulation of glutamine transport; ISO:MGI.
DR   GO; GO:0010888; P:negative regulation of lipid storage; ISO:MGI.
DR   GO; GO:0009892; P:negative regulation of metabolic process; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISO:MGI.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; ISO:MGI.
DR   GO; GO:0006909; P:phagocytosis; IDA:UniProtKB.
DR   GO; GO:0001890; P:placenta development; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:MGI.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; IMP:YuBioLab.
DR   GO; GO:0048639; P:positive regulation of developmental growth; ISO:MGI.
DR   GO; GO:1904651; P:positive regulation of fat cell apoptotic process; ISO:MGI.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; ISO:MGI.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISO:MGI.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISS:UniProtKB.
DR   GO; GO:0043270; P:positive regulation of ion transport; ISO:MGI.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0035360; P:positive regulation of peroxisome proliferator activated receptor signaling pathway; ISO:MGI.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISO:MGI.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IDA:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; ISO:MGI.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; ISO:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; ISO:MGI.
DR   GO; GO:0032310; P:prostaglandin secretion; ISS:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; ISO:MGI.
DR   GO; GO:0046850; P:regulation of bone remodeling; IMP:UniProtKB.
DR   GO; GO:0090335; P:regulation of brown fat cell differentiation; IDA:UniProtKB.
DR   GO; GO:0050790; P:regulation of catalytic activity; IMP:MGI.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; IGI:MGI.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; IMP:MGI.
DR   GO; GO:0050796; P:regulation of insulin secretion; IMP:MGI.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IDA:MGI.
DR   GO; GO:0046890; P:regulation of lipid biosynthetic process; IGI:MGI.
DR   GO; GO:0060587; P:regulation of lipoprotein lipid oxidation; ISO:MGI.
DR   GO; GO:0019222; P:regulation of metabolic process; IMP:MGI.
DR   GO; GO:0032814; P:regulation of natural killer cell activation; ISS:UniProtKB.
DR   GO; GO:0042269; P:regulation of natural killer cell mediated cytotoxicity; ISS:UniProtKB.
DR   GO; GO:0032817; P:regulation of natural killer cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IMP:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050810; P:regulation of steroid biosynthetic process; IMP:MGI.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0002021; P:response to dietary excess; IMP:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IMP:MGI.
DR   GO; GO:0033197; P:response to vitamin E; IEA:Ensembl.
DR   GO; GO:0019953; P:sexual reproduction; IMP:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:BHF-UCL.
DR   Gene3D; 1.20.1250.10; -; 1.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR000065; Leptin.
DR   PANTHER; PTHR11724; LEPTIN; 1.
DR   PANTHER; PTHR11724:SF1; LEPTIN; 1.
DR   Pfam; PF02024; Leptin; 1.
DR   PIRSF; PIRSF001837; Leptin; 1.
DR   PRINTS; PR00495; LEPTIN.
DR   SUPFAM; SSF47266; 4-helical cytokines; 1.
PE   1: Evidence at protein level;
KW   Diabetes mellitus; Disulfide bond; Obesity; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..167
FT                   /note="Leptin"
FT                   /id="PRO_0000017687"
FT   DISULFID        117..167
FT                   /evidence="ECO:0000250"
FT   VARIANT         49
FT                   /note="Missing (in 30% the clones)"
SQ   SEQUENCE   167 AA;  18709 MW;  D6783E6C76FD7116 CRC64;
     MCWRPLCRFL WLWSYLSYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS VSAKQRVTGL
     DFIPGLHPIL SLSKMDQTLA VYQQVLTSLP SQNVLQIAND LENLRDLLHL LAFSKSCSLP
     QTSGLQKPES LDGVLEASLY STEVVALSRL QGSLQDILQQ LDVSPEC
//
ID   PHEX_HUMAN              Reviewed;         749 AA.
AC   P78562; O00678; Q13646; Q2M325; Q93032; Q99827;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   22-FEB-2023, entry version 200.
DE   RecName: Full=Phosphate-regulating neutral endopeptidase PHEX;
DE            EC=3.4.24.- {ECO:0000269|PubMed:18597632, ECO:0000269|PubMed:9593714};
DE   AltName: Full=Metalloendopeptidase homolog PEX;
DE   AltName: Full=Vitamin D-resistant hypophosphatemic rickets protein;
DE   AltName: Full=X-linked hypophosphatemia protein;
DE            Short=HYP;
GN   Name=PHEX; Synonyms=PEX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLHR ARG-85; LEU-534;
RP   ARG-579 AND PRO-651.
RX   PubMed=9199930; DOI=10.1101/gr.7.6.573;
RA   Francis F., Strom T.M., Hennig S., Boeddrich A., Lorenz B., Brandau O.,
RA   Mohnike K.L., Cagnoli M., Steffens C., Klages S., Borzym K., Pohl T.,
RA   Oudet C.L., Econs M.J., Rowe P.S.N., Reinhardt R., Meitinger T.,
RA   Lehrach H.;
RT   "Genomic organization of the human PEX gene mutated in X-linked dominant
RT   hypophosphatemic rickets.";
RL   Genome Res. 7:573-585(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE.
RX   PubMed=9077527; DOI=10.1172/jci119276;
RA   Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C.,
RA   Goodyer C.G., Tenenhouse H.S.;
RT   "Pex/PEX tissue distribution and evidence for a deletion in the 3' region
RT   of the Pex gene in X-linked hypophosphatemic mice.";
RL   J. Clin. Invest. 99:1200-1209(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone;
RX   PubMed=9199999; DOI=10.1359/jbmr.1997.12.7.1009;
RA   Guo R., Quarles L.D.;
RT   "Cloning and sequencing of human PEX from a bone cDNA library: evidence for
RT   its developmental stage-specific regulation in osteoblasts.";
RL   J. Bone Miner. Res. 12:1009-1017(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=9070861; DOI=10.1006/bbrc.1997.6153;
RA   Grieff M., Mumm S., Waeltz P., Mazzarella R., Whyte M.P., Thakker R.V.,
RA   Schlessinger D.;
RT   "Expression and cloning of the human X-linked hypophosphatemia gene cDNA.";
RL   Biochem. Biophys. Res. Commun. 231:635-639(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND TOPOLOGY.
RX   PubMed=9593714; DOI=10.1074/jbc.273.22.13729;
RA   Lipman M.L., Panda D., Bennett H.P., Henderson J.E., Shane E., Shen Y.,
RA   Goltzman D., Karaplis A.C.;
RT   "Cloning of human PEX cDNA. Expression, subcellular localization, and
RT   endopeptidase activity.";
RL   J. Biol. Chem. 273:13729-13737(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLHR TYR-85; CYS-166;
RP   SER-252; ILE-253 AND VAL-579.
RX   PubMed=9106524;
RA   Holm I.A., Huang X., Kunkel L.M.;
RT   "Mutational analysis of the PEX gene in patients with X-linked
RT   hypophosphatemic rickets.";
RL   Am. J. Hum. Genet. 60:790-797(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-641.
RX   PubMed=7550339; DOI=10.1038/ng1095-130;
RG   The HYP consortium;
RA   Francis F., Hennig S., Korn B., Reinhardt R., de Jong P., Poustka A.,
RA   Lehrach H., Rowe P.S.N., Goulding J.N., Summerfield T., Mountford R.,
RA   Read A.P., Popowska E., Pronicka E., Davies K.E., Oriordan J.L.H.,
RA   Econs M.J., Nesbitt T., Drezner M.K., Oudet C.L., Pannetier S., Hanauer A.,
RA   Strom T.M., Meindl A., Lorenz B., Cagnoli M., Mohnike K.L., Murken J.,
RA   Meitinger T.;
RT   "A gene (PEX) with homologies to endopeptidases is mutated in patients with
RT   X-linked hypophosphatemic rickets.";
RL   Nat. Genet. 11:130-136(1995).
RN   [10]
RP   FUNCTION.
RX   PubMed=12220505; DOI=10.1016/s0006-291x(02)02125-3;
RA   Guo R., Rowe P.S., Liu S., Simpson L.G., Xiao Z.S., Quarles L.D.;
RT   "Inhibition of MEPE cleavage by Phex.";
RL   Biochem. Biophys. Res. Commun. 297:38-45(2002).
RN   [11]
RP   COFACTOR, AND INTERACTION WITH MEPE.
RX   PubMed=15664000; DOI=10.1016/j.bone.2004.09.015;
RA   Rowe P.S., Garrett I.R., Schwarz P.M., Carnes D.L., Lafer E.M., Mundy G.R.,
RA   Gutierrez G.E.;
RT   "Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the
RT   MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets
RT   (HYP).";
RL   Bone 36:33-46(2005).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MEPE.
RX   PubMed=18162525; DOI=10.1210/en.2007-1205;
RA   Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M.,
RA   Rowe P.S.;
RT   "Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides
RT   (minhibins): ASARM-peptide(s) are directly responsible for defective
RT   mineralization in HYP.";
RL   Endocrinology 149:1757-1772(2008).
RN   [13]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=18597632; DOI=10.1359/jbmr.080601;
RA   Addison W.N., Nakano Y., Loisel T., Crine P., McKee M.D.;
RT   "MEPE-ASARM peptides control extracellular matrix mineralization by binding
RT   to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.";
RL   J. Bone Miner. Res. 23:1638-1649(2008).
RN   [14]
RP   VARIANTS XLHR SER-77; PRO-138; LEU-534 AND ARG-579.
RX   PubMed=9097956; DOI=10.1093/hmg/6.4.539;
RA   Rowe P.S.N., Oudet C.L., Francis F., Sinding C., Pannetier S., Econs M.J.,
RA   Strom T.M., Meitinger T., Garabedian M., David A., Macher M.-A.,
RA   Questiaux E., Popowska E., Pronicka E., Read A.P., Mokrzycki A.,
RA   Glorieux F.H., Drezner M.K., Hanauer A., Lehrach H., Goulding J.N.,
RA   O'Riordan J.L.H.;
RT   "Distribution of mutations in the PEX gene in families with X-linked
RT   hypophosphataemic rickets (HYP).";
RL   Hum. Mol. Genet. 6:539-549(1997).
RN   [15]
RP   VARIANT XLHR PRO-555.
RX   PubMed=9768646; DOI=10.1210/jcem.83.10.5167;
RA   Econs M.J., Friedman N.E., Rowe P.S.N., Speer M.C., Francis F., Strom T.M.,
RA   Oudet C.L., Smith J.A., Ninomiya J.T., Lee B.E., Bergen H.;
RT   "A PHEX gene mutation is responsible for adult-onset vitamin D-resistant
RT   hypophosphatemic osteomalacia: evidence that the disorder is not a distinct
RT   entity from X-linked hypophosphatemic rickets.";
RL   J. Clin. Endocrinol. Metab. 83:3459-3462(1998).
RN   [16]
RP   VARIANTS XLHR PHE-317; LEU-534; ARG-579; ARG-621; ASN-680 DEL; THR-720;
RP   TYR-731 AND ARG-749.
RX   PubMed=9768674; DOI=10.1210/jcem.83.10.5180;
RA   Dixon P.H., Christie P.T., Wooding C., Trump D., Grieff M., Holm I.A.,
RA   Gertner J.M., Schmidtke J., Shah B., Shaw N., Smith C., Tau C.,
RA   Schlessinger D., Whyte M.P., Thakker R.V.;
RT   "Mutational analysis of PHEX gene in X-linked hypophosphatemia.";
RL   J. Clin. Endocrinol. Metab. 83:3615-3623(1998).
RN   [17]
RP   VARIANTS XLHR SER-80; PHE-142; GLY-237; CYS-530; ASP-573; SER-733 AND
RP   TRP-746.
RX   PubMed=10439971; DOI=10.1038/sj.ejhg.5200341;
RA   Filisetti D., Ostermann G., von Bredow M., Strom T.M., Filler G.,
RA   Ehrich J., Pannetier S., Garnier J.-M., Rowe P.S.N., Francis F.,
RA   Julienne A., Hanauer A., Econs M.J., Oudet C.L.;
RT   "Non-random distribution of mutations in the PHEX gene, and under-detected
RT   missense mutations at non-conserved residues.";
RL   Eur. J. Hum. Genet. 7:615-619(1999).
RN   [18]
RP   VARIANTS XLHR PHE-85; PRO-141; VAL-341 DEL; PRO-567; LYS-680 AND TYR-693.
RX   PubMed=10737991;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<383::aid-humu18>3.0.co;2-#;
RA   Tyynismaa H., Kaitila I., Naentoe-Salonen K., Ala-Houhala M., Alitalo T.;
RT   "Identification of fifteen novel PHEX gene mutations in Finnish patients
RT   with hypophosphatemic rickets.";
RL   Hum. Mutat. 15:383-384(2000).
RN   [19]
RP   VARIANTS XLHR ARG-160 AND ASN-444 INS.
RX   PubMed=11004247; DOI=10.1203/00006450-200010000-00019;
RA   Sato K., Tajima T., Nakae J., Adachi M., Asakura Y., Tachibana K., Suwa S.,
RA   Katsumata N., Tanaka T., Hayashi Y., Abe S., Murashita M., Okuhara K.,
RA   Shinohara N., Fujieda K.;
RT   "Three novel PHEX gene mutations in Japanese patients with X-linked
RT   hypophosphatemic rickets.";
RL   Pediatr. Res. 48:536-540(2000).
CC   -!- FUNCTION: Peptidase that cleaves SIBLING (small integrin-binding
CC       ligand, N-linked glycoprotein)-derived ASARM peptides, thus regulating
CC       their biological activity (PubMed:9593714, PubMed:15664000,
CC       PubMed:18162525, PubMed:18597632). Cleaves ASARM peptides between Ser
CC       and Glu or Asp residues (PubMed:18597632). Regulates osteogenic cell
CC       differentiation and bone mineralization through the cleavage of the
CC       MEPE-derived ASARM peptide (PubMed:18597632). Promotes dentin
CC       mineralization and renal phosphate reabsorption by cleaving DMP1- and
CC       MEPE-derived ASARM peptides (PubMed:18597632, PubMed:18162525).
CC       Inhibits the cleavage of MEPE by CTSB/cathepsin B thus preventing MEPE
CC       degradation (PubMed:12220505). {ECO:0000250|UniProtKB:P70669,
CC       ECO:0000269|PubMed:12220505, ECO:0000269|PubMed:18162525,
CC       ECO:0000269|PubMed:18597632}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:15664000};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:15664000};
CC   -!- SUBUNIT: Interacts with MEPE; the interaction is zinc-dependent (via
CC       ASARM motif). {ECO:0000269|PubMed:15664000,
CC       ECO:0000269|PubMed:18162525}.
CC   -!- INTERACTION:
CC       P78562; Q9NQ76: MEPE; NbExp=2; IntAct=EBI-2827676, EBI-1753293;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9593714};
CC       Single-pass type II membrane protein {ECO:0000269|PubMed:9593714}.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in ovary (PubMed:9070861).
CC       Expressed at low levels in kidney (PubMed:9070861).
CC       {ECO:0000269|PubMed:9070861}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal lung (PubMed:9070861,
CC       PubMed:9077527). Expressed in fetal calvaria and to a lesser extent in
CC       fetal kidney and skeletal muscles (PubMed:9593714, PubMed:9077527).
CC       {ECO:0000269|PubMed:9070861, ECO:0000269|PubMed:9077527,
CC       ECO:0000269|PubMed:9593714}.
CC   -!- DISEASE: Hypophosphatemic rickets, X-linked dominant (XLHR)
CC       [MIM:307800]: A disorder characterized by impaired phosphate uptake in
CC       the kidney, which is likely to be caused by abnormal regulation of
CC       sodium phosphate cotransport in the proximal tubules. Clinical
CC       manifestations include skeletal deformities, growth failure,
CC       craniosynostosis, paravertebral calcifications, pseudofractures in
CC       lower extremities, and muscular hypotonia with onset in early
CC       childhood. X-linked hypophosphatemic rickets is the most common form of
CC       hypophosphatemia with an incidence of 1 in 20000.
CC       {ECO:0000269|PubMed:10439971, ECO:0000269|PubMed:10737991,
CC       ECO:0000269|PubMed:11004247, ECO:0000269|PubMed:9097956,
CC       ECO:0000269|PubMed:9106524, ECO:0000269|PubMed:9199930,
CC       ECO:0000269|PubMed:9768646, ECO:0000269|PubMed:9768674}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the peptidase M13 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01233, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y08111; CAA69326.1; -; Genomic_DNA.
DR   EMBL; Y08112; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08113; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08114; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08115; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08116; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08117; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08118; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08119; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08120; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08121; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08122; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08123; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08124; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08125; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08126; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08127; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08128; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08129; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08130; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08131; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; Y08132; CAA69326.1; JOINED; Genomic_DNA.
DR   EMBL; U75645; AAB47749.1; -; mRNA.
DR   EMBL; U87284; AAB47562.1; -; mRNA.
DR   EMBL; AD000712; AAB51604.1; -; mRNA.
DR   EMBL; AH004966; AAB42219.1; -; Genomic_DNA.
DR   EMBL; U82970; AAC24487.1; -; mRNA.
DR   EMBL; U73024; AAD08630.1; -; Genomic_DNA.
DR   EMBL; Y10196; CAA71258.1; -; Genomic_DNA.
DR   EMBL; BC105057; AAI05058.1; -; mRNA.
DR   EMBL; BC105059; AAI05060.1; -; mRNA.
DR   EMBL; U60475; AAC50552.1; -; mRNA.
DR   CCDS; CCDS14204.1; -.
DR   RefSeq; NP_000435.3; NM_000444.5.
DR   RefSeq; NP_001269683.1; NM_001282754.1.
DR   AlphaFoldDB; P78562; -.
DR   SMR; P78562; -.
DR   BioGRID; 111270; 3.
DR   IntAct; P78562; 3.
DR   STRING; 9606.ENSP00000368682; -.
DR   MEROPS; M13.091; -.
DR   GlyCosmos; P78562; 8 sites, No reported glycans.
DR   GlyGen; P78562; 8 sites.
DR   iPTMnet; P78562; -.
DR   PhosphoSitePlus; P78562; -.
DR   BioMuta; PHEX; -.
DR   DMDM; 2499917; -.
DR   EPD; P78562; -.
DR   jPOST; P78562; -.
DR   MassIVE; P78562; -.
DR   PaxDb; P78562; -.
DR   PeptideAtlas; P78562; -.
DR   ProteomicsDB; 57655; -.
DR   Antibodypedia; 24481; 138 antibodies from 26 providers.
DR   DNASU; 5251; -.
DR   Ensembl; ENST00000379374.5; ENSP00000368682.4; ENSG00000102174.10.
DR   GeneID; 5251; -.
DR   KEGG; hsa:5251; -.
DR   MANE-Select; ENST00000379374.5; ENSP00000368682.4; NM_000444.6; NP_000435.3.
DR   UCSC; uc004dah.5; human.
DR   AGR; HGNC:8918; -.
DR   CTD; 5251; -.
DR   DisGeNET; 5251; -.
DR   GeneCards; PHEX; -.
DR   GeneReviews; PHEX; -.
DR   HGNC; HGNC:8918; PHEX.
DR   HPA; ENSG00000102174; Tissue enhanced (lung).
DR   MalaCards; PHEX; -.
DR   MIM; 300550; gene.
DR   MIM; 307800; phenotype.
DR   neXtProt; NX_P78562; -.
DR   OpenTargets; ENSG00000102174; -.
DR   Orphanet; 89936; X-linked hypophosphatemia.
DR   PharmGKB; PA33258; -.
DR   VEuPathDB; HostDB:ENSG00000102174; -.
DR   eggNOG; KOG3624; Eukaryota.
DR   GeneTree; ENSGT00940000157313; -.
DR   HOGENOM; CLU_006187_4_1_1; -.
DR   InParanoid; P78562; -.
DR   OMA; YSSYYWK; -.
DR   OrthoDB; 202716at2759; -.
DR   PhylomeDB; P78562; -.
DR   TreeFam; TF315192; -.
DR   BRENDA; 3.4.24.B15; 2681.
DR   PathwayCommons; P78562; -.
DR   SignaLink; P78562; -.
DR   BioGRID-ORCS; 5251; 19 hits in 771 CRISPR screens.
DR   ChiTaRS; PHEX; human.
DR   GeneWiki; PHEX; -.
DR   GenomeRNAi; 5251; -.
DR   Pharos; P78562; Tbio.
DR   PRO; PR:P78562; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P78562; protein.
DR   Bgee; ENSG00000102174; Expressed in secondary oocyte and 91 other tissues.
DR   Genevisible; P78562; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0071374; P:cellular response to parathyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0019637; P:organophosphate metabolic process; IEA:Ensembl.
DR   GO; GO:0036211; P:protein modification process; TAS:ProtInc.
DR   GO; GO:0016485; P:protein processing; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0060416; P:response to growth hormone; IEA:Ensembl.
DR   GO; GO:1990418; P:response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1904383; P:response to sodium phosphate; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   CDD; cd08662; M13; 1.
DR   Gene3D; 3.40.390.10; Collagenase (Catalytic Domain); 1.
DR   Gene3D; 1.10.1380.10; Neutral endopeptidase , domain2; 1.
DR   InterPro; IPR024079; MetalloPept_cat_dom_sf.
DR   InterPro; IPR000718; Peptidase_M13.
DR   InterPro; IPR018497; Peptidase_M13_C.
DR   InterPro; IPR042089; Peptidase_M13_dom_2.
DR   InterPro; IPR008753; Peptidase_M13_N.
DR   PANTHER; PTHR11733:SF133; PHOSPHATE-REGULATING NEUTRAL ENDOPEPTIDASE PHEX; 1.
DR   PANTHER; PTHR11733; ZINC METALLOPROTEASE FAMILY M13 NEPRILYSIN-RELATED; 1.
DR   Pfam; PF01431; Peptidase_M13; 1.
DR   Pfam; PF05649; Peptidase_M13_N; 1.
DR   PRINTS; PR00786; NEPRILYSIN.
DR   SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 1.
DR   PROSITE; PS51885; NEPRILYSIN; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   Biomineralization; Cell membrane; Disease variant; Disulfide bond;
KW   Glycoprotein; Hydrolase; Membrane; Metal-binding; Metalloprotease;
KW   Protease; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   CHAIN           1..749
FT                   /note="Phosphate-regulating neutral endopeptidase PHEX"
FT                   /id="PRO_0000078228"
FT   TOPO_DOM        1..20
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:9593714"
FT   TRANSMEM        21..41
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000269|PubMed:9593714"
FT   TOPO_DOM        42..641
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:9593714"
FT   DOMAIN          53..749
FT                   /note="Peptidase M13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   ACT_SITE        581
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   ACT_SITE        646
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   BINDING         580
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         584
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         642
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   CARBOHYD        71
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        238
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        263
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        290
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        301
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        377
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        484
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        736
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        54..59
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        77..733
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        85..693
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        142..406
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        617..746
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   VARIANT         77
FT                   /note="C -> S (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9097956"
FT                   /id="VAR_006738"
FT   VARIANT         80
FT                   /note="F -> S (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010616"
FT   VARIANT         85
FT                   /note="C -> F (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010617"
FT   VARIANT         85
FT                   /note="C -> R (in XLHR; dbSNP:rs1556014287)"
FT                   /evidence="ECO:0000269|PubMed:9199930"
FT                   /id="VAR_010618"
FT   VARIANT         85
FT                   /note="C -> Y (in XLHR; dbSNP:rs137853269)"
FT                   /evidence="ECO:0000269|PubMed:9106524"
FT                   /id="VAR_006739"
FT   VARIANT         138
FT                   /note="L -> P (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9097956"
FT                   /id="VAR_006740"
FT   VARIANT         141
FT                   /note="S -> P (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010619"
FT   VARIANT         142
FT                   /note="C -> F (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010620"
FT   VARIANT         160
FT                   /note="L -> R (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:11004247"
FT                   /id="VAR_010621"
FT   VARIANT         166
FT                   /note="R -> C (in XLHR; dbSNP:rs751230094)"
FT                   /evidence="ECO:0000269|PubMed:9106524"
FT                   /id="VAR_006741"
FT   VARIANT         237
FT                   /note="D -> G (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010622"
FT   VARIANT         252
FT                   /note="F -> S (in XLHR; dbSNP:rs267606945)"
FT                   /evidence="ECO:0000269|PubMed:9106524"
FT                   /id="VAR_006742"
FT   VARIANT         253
FT                   /note="M -> I (in XLHR; dbSNP:rs267606946)"
FT                   /evidence="ECO:0000269|PubMed:9106524"
FT                   /id="VAR_006743"
FT   VARIANT         317
FT                   /note="Y -> F (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010623"
FT   VARIANT         341
FT                   /note="Missing (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010624"
FT   VARIANT         444
FT                   /note="W -> WN (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:11004247"
FT                   /id="VAR_010625"
FT   VARIANT         530
FT                   /note="W -> C (in XLHR; dbSNP:rs1556091855)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010626"
FT   VARIANT         534
FT                   /note="P -> L (in XLHR; dbSNP:rs886041363)"
FT                   /evidence="ECO:0000269|PubMed:9097956,
FT                   ECO:0000269|PubMed:9199930, ECO:0000269|PubMed:9768674"
FT                   /id="VAR_006744"
FT   VARIANT         555
FT                   /note="L -> P (in XLHR; dbSNP:rs137853270)"
FT                   /evidence="ECO:0000269|PubMed:9768646"
FT                   /id="VAR_010627"
FT   VARIANT         567
FT                   /note="R -> P (in XLHR; sporadic; dbSNP:rs760870713)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010628"
FT   VARIANT         573
FT                   /note="A -> D (in XLHR; sporadic; dbSNP:rs1556135308)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010629"
FT   VARIANT         579
FT                   /note="G -> R (in XLHR; dbSNP:rs875989883)"
FT                   /evidence="ECO:0000269|PubMed:9097956,
FT                   ECO:0000269|PubMed:9199930, ECO:0000269|PubMed:9768674"
FT                   /id="VAR_006745"
FT   VARIANT         579
FT                   /note="G -> V (in XLHR; dbSNP:rs1057517980)"
FT                   /evidence="ECO:0000269|PubMed:9106524"
FT                   /id="VAR_006746"
FT   VARIANT         621
FT                   /note="Q -> R (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010630"
FT   VARIANT         651
FT                   /note="R -> P (in XLHR; dbSNP:rs748792378)"
FT                   /evidence="ECO:0000269|PubMed:9199930"
FT                   /id="VAR_010631"
FT   VARIANT         680
FT                   /note="N -> K (in XLHR; sporadic; dbSNP:rs1556151526)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010633"
FT   VARIANT         680
FT                   /note="Missing (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010632"
FT   VARIANT         693
FT                   /note="C -> Y (in XLHR; sporadic; dbSNP:rs1556200989)"
FT                   /evidence="ECO:0000269|PubMed:10737991"
FT                   /id="VAR_010634"
FT   VARIANT         720
FT                   /note="A -> T (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010635"
FT   VARIANT         731
FT                   /note="F -> Y (in XLHR)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010636"
FT   VARIANT         733
FT                   /note="C -> S (in XLHR; sporadic; dbSNP:rs1057517981)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010637"
FT   VARIANT         746
FT                   /note="C -> W (in XLHR; sporadic)"
FT                   /evidence="ECO:0000269|PubMed:10439971"
FT                   /id="VAR_010638"
FT   VARIANT         749
FT                   /note="W -> R (in XLHR; dbSNP:rs1556206403)"
FT                   /evidence="ECO:0000269|PubMed:9768674"
FT                   /id="VAR_010639"
FT   CONFLICT        363
FT                   /note="A -> D (in Ref. 9; AAC50552)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        403
FT                   /note="W -> R (in Ref. 9; AAC50552)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        641
FT                   /note="G -> A (in Ref. 9; AAC50552)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   749 AA;  86474 MW;  7C4F9F3E2471C6A8 CRC64;
     MEAETGSSVE TGKKANRGTR IALVVFVGGT LVLGTILFLV SQGLLSLQAK QEYCLKPECI
     EAAAAILSKV NLSVDPCDNF FRFACDGWIS NNPIPEDMPS YGVYPWLRHN VDLKLKELLE
     KSISRRRDTE AIQKAKILYS SCMNEKAIEK ADAKPLLHIL RHSPFRWPVL ESNIGPEGVW
     SERKFSLLQT LATFRGQYSN SVFIRLYVSP DDKASNEHIL KLDQATLSLA VREDYLDNST
     EAKSYRDALY KFMVDTAVLL GANSSRAEHD MKSVLRLEIK IAEIMIPHEN RTSEAMYNKM
     NISELSAMIP QFDWLGYIKK VIDTRLYPHL KDISPSENVV VRVPQYFKDL FRILGSERKK
     TIANYLVWRM VYSRIPNLSR RFQYRWLEFS RVIQGTTTLL PQWDKCVNFI ESALPYVVGK
     MFVDVYFQED KKEMMEELVE GVRWAFIDML EKENEWMDAG TKRKAKEKAR AVLAKVGYPE
     FIMNDTHVNE DLKAIKFSEA DYFGNVLQTR KYLAQSDFFW LRKAVPKTEW FTNPTTVNAF
     YSASTNQIRF PAGELQKPFF WGTEYPRSLS YGAIGVIVGH EFTHGFDNNG RKYDKNGNLD
     PWWSTESEEK FKEKTKCMIN QYSNYYWKKA GLNVKGKRTL GENIADNGGL REAFRAYRKW
     INDRRQGLEE PLLPGITFTN NQLFFLSYAH VRCNSYRPEA AREQVQIGAH SPPQFRVNGA
     ISNFEEFQKA FNCPPNSTMN RGMDSCRLW
//
